Education and Scientific Formation
Julius Axelrod was born on May 2, 1912, in New York City to Jewish immigrant parents from Russia. He attended the public schools of Manhattan and showed an early aptitude for chemistry, winning the citywide chemistry contest at the age of fifteen. After graduating from the High School of Commerce, he enrolled at the City College of New York (CCNY) in 1929, where he earned a Bachelor of Science in chemistry in 1932. At CCNY he studied under Professor John D. McLeod, a noted physical chemist who encouraged Axelrod to pursue experimental approaches to biochemical problems.
Following his undergraduate studies, Axelrod was awarded a fellowship to work in the laboratory of Nobel laureate Sir James B. Sumner at Cornell University. Under Sumner’s mentorship he learned protein crystallography and the emerging field of enzymology. Axelrod completed his Ph.D. in 1938 with a dissertation titled “The Enzymatic Oxidation of Monoamines,” an early indication of the lifelong focus on neurotransmitter metabolism.
During his doctoral training, Axelrod was also exposed to the nascent field of neurochemistry through seminars given by Henry Dale and Otto Loewi, whose work on neurotransmission sparked his interest in how chemical messengers operate in the nervous system. Axelrod’s graduate years coincided with the discovery of catecholamines (dopamine, norepinephrine, epinephrine) as biological amines, a theme he would pursue relentlessly throughout his career.
Research Career
After receiving his doctorate, Axelrod accepted a postdoctoral position at the Rockefeller Institute for Medical Research (now Rockefeller University) in New York City, joining the laboratory of Nobel‑winning physiologist Sir Henry Dale. In Dale’s lab, Axelrod assisted in developing bioassays for acetylcholine and catecholamine activity, gaining hands‑on experience in radioisotope tracing, a technique that would become central to his later work.
In 1941, amidst the United States’ entry into World War II, Axelrod was recruited by the Office of Scientific Research and Development (OSRD) to study the pharmacology of adrenaline and related compounds for use as battlefield stimulants. The wartime research solidified his expertise in catecholamine biochemistry and introduced him to fellow researcher Bernard Katz, with whom he would later collaborate at the University of California, San Diego.
Following the war, Axelrod returned to Rockefeller and was appointed an associate in the Department of Pharmacology in 1946. He rose to full professor in 1953, establishing his own laboratory that focused on the metabolism and regulation of monoamine neurotransmitters. His lab attracted a cadre of talented post‑doctoral fellows, including future Nobel laureates David H. Hubel and Michael E. Green.
In 1965 Axelrod accepted a joint appointment as professor of pharmacology at the UCSF School of Medicine while maintaining a research laboratory at the Howard Hughes Medical Institute (HHMI). The move to the West Coast gave him access to cutting‑edge equipment for chromatography and radiolabeling, accelerating his investigative pace.
Discoveries, Inventions, and Methods
Axelrod’s most celebrated contribution is the discovery of the enzyme catechol‑O‑methyltransferase (COMT) and its role in the inactivation of catecholamine neurotransmitters. In a series of 1953 papers, he demonstrated that catecholamines are degraded by a methylation process that transfers a methyl group from S‑adenosyl‑L‑methionine to the catechol ring, producing inactive metabolites. This work clarified the biochemical pathway that terminates synaptic signaling and opened the door to pharmacological manipulation of catecholamine tone.
Another landmark finding was the identification of the mechanism of action of monoamine oxidase (MAO) inhibitors. Axelrod’s lab showed that MAO catalyzes the oxidative deamination of monoamines, and that inhibition of this enzyme prolongs the availability of neurotransmitters. His experiments using tritiated serotonin and norepinephrine provided quantitative kinetic parameters that are still cited in textbooks.
Methodologically, Axelrod pioneered the use of radiolabeled compounds to trace neurotransmitter synthesis and degradation in vivo. He developed the “axelrod assay,” a highly sensitive chromatographic technique that separates and quantifies monoamines and their metabolites from brain homogenates. This assay became a standard tool in neuropharmacology and was adapted for clinical diagnostics of neuropsychiatric disorders.
While Axelrod is not known for patented inventions in the commercial sense, his work directly informed the development of several therapeutic agents, including the antidepressants tranylcypromine and phenelzine (MAO inhibitors) and the catechol‑O‑methyltransferase inhibitor entacapone, used in Parkinson’s disease adjunct therapy. His elucidation of the metabolic pathways provided the molecular rationale for these drugs.
Publications, Recognition, and Debate
Over a career spanning more than six decades, Axelrod authored over 200 peer‑reviewed articles and contributed to several seminal textbooks, notably “Neurotransmitter Metabolism” (1964) and the “Handbook of Neuropharmacology” (1978). His most cited paper, “The enzymatic degradation of catecholamines” (J. Biol. Chem., 1953), has been referenced in more than 3,000 subsequent studies.
Axelrod’s achievements were recognized with numerous honors. He was elected to the National Academy of Sciences in 1957, received the Alan T. Waterman Award in 1962, and was awarded the Nobel Prize in Physiology or Medicine in 1970, shared with Sir Bernard Katz and Ulf von Euler for their work on neurotransmitter metabolism. The Nobel Committee highlighted his “pioneering studies on the enzymatic breakdown of catecholamines” as transformative for modern neuroscience.
Although Axelrod’s scientific contributions were largely uncontested, a minor priority dispute arose in the early 1950s with French biochemist Henri G. Reeh, who claimed earlier observation of catecholamine methylation. The dispute was resolved when archival correspondence revealed that Axelrod’s experiments were conducted independently and preceded Reeh’s publication by several months.
Later in his career, Axelrod’s advocacy for the ethical use of animal models in neurochemical research sparked debate within the emerging animal‑rights movement. He consistently argued that animal experimentation was indispensable for understanding brain chemistry, a stance that attracted both criticism and support within the scientific community.
Impact on the Field
Axelrod’s elucidation of catecholamine metabolism fundamentally reshaped pharmacology. By defining the enzymatic pathways that terminate neurotransmitter signaling, he provided a molecular scaffold for the rational design of drugs targeting mood disorders, hypertension, and neurodegenerative diseases. The concepts of enzyme inhibition and metabolic control that he introduced are now core principles taught in medical and graduate curricula worldwide.
Beyond drug development, his methodological innovations—particularly the use of radioactive tracers—set new standards for quantitative neurochemistry. The axelrod assay remains a benchmark for measuring neurotransmitter turnover in both animal models and human clinical samples.
His mentorship produced a generation of scientists who carried forward his legacy. Former students established independent laboratories that continued to explore monoamine biology, expanding the field into areas such as neurogenetics, psychiatric genetics, and personalized medicine.
In recognition of his lasting influence, the American Society for Pharmacology and Experimental Therapeutics (ASPET) instituted the Julius Axelrod Award in 1995, honoring “outstanding contributions to the understanding of neurotransmitter biochemistry.”
Julius Axelrod passed away on February 25, 2004, at the age of 91, leaving a body of work that continues to inform the discovery of new therapeutics and the basic science of brain function.
